Related Experiment Video
Updated: Dec 7, 2025

Ameliorating Osteoarthritis in Mice Using Silver Nanoparticles
Published on: June 2, 2023
Targeted silver nanoparticles for rheumatoid arthritis therapy via macrophage apoptosis and Re-polarization
Yihua Yang1, Lina Guo2, Zhe Wang2
1Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, Hunan, 410013, China; Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, School of Pharmaceutical Sciences, Xuzhou Medical University, Xuzhou, Jiangsu, 221004, China.
Abstract:
Infiltration of inflammatory cells, especially the M1 macrophages that secrete various types of inflammation cytokines, play crucial roles in the pathogenesis of rheumatoid arthritis (RA). To relief synovial inflammation, M1 macrophages must be eliminated or switched to anti-inflammatory M2 phenotype. We herein developed folic acid modified silver nanoparticles (FA-AgNPs) that can actively deliver into M1 macrophages to synergistically induce M1 macrophages reduction and M2 macrophages polarization for effective RA treatment. The AgNPs was facilely prepared, PEGylated and modified with FA to realize M1 macrophages targeting delivery via folate receptor overexpressed on M1 macrophages surface. After entering cells, FA-AgNPs dissolved and released Ag+ in response to intracellular glutathione (GSH), which is the key element to exert a series of anti-inflammatory functions, such as M1 macrophages apoptosis and reactive oxygen species (ROS) scavenging to facilitate M2 macrophages polarization, both of which contributed to RA treatment. This nano-system could passively accumulate into inflamed joints, permit potent anti-inflammatory activity, and impose strong therapeutic efficacy in mice RA models with high biosafety. After treatment, FA-AgNPs could be gradually cleared from the body mainly via feces without tissue accumulation, and did not show any appreciable long-term toxicity. This work declares the first example of using bio-active nanoparticles for RA treatment without loading any drugs, and highlights the potential of FA-AgNPs for targeted RA therapy via simultaneous M1 macrophage apoptosis and M1-to-M2 macrophages re-polarization.
Insights
Folic acid-modified silver nanoparticles target M1 macrophages, reducing inflammation and promoting M2 polarization for rheumatoid arthritis (RA) treatment. This drug-free nanoparticle approach shows high efficacy and biosafety in RA models.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Immunology
Background:
- Rheumatoid arthritis (RA) pathogenesis involves M1 macrophages secreting inflammatory cytokines.
- Targeting M1 macrophages for elimination or repolarization to M2 phenotype is crucial for RA treatment.
Purpose of the Study:
- To develop folic acid-modified silver nanoparticles (FA-AgNPs) for targeted M1 macrophage delivery.
- To investigate the synergistic effect of FA-AgNPs in reducing M1 macrophages and promoting M2 polarization for RA therapy.
Main Methods:
- Facile preparation and PEGylation of silver nanoparticles (AgNPs).
- Modification of AgNPs with folic acid (FA) for M1 macrophage targeting via folate receptors.
- In vitro and in vivo evaluation of FA-AgNPs in RA models, assessing M1 macrophage apoptosis, M2 polarization, and therapeutic efficacy.
Main Results:
- FA-AgNPs demonstrated targeted delivery to M1 macrophages overexpressing folate receptors.
- Released Ag+ ions induced M1 macrophage apoptosis and ROS scavenging, facilitating M2 polarization.
- FA-AgNPs showed significant therapeutic efficacy in mice RA models with high biosafety and efficient clearance.
Conclusions:
- FA-AgNPs offer a novel, drug-free therapeutic strategy for RA by simultaneously inducing M1 macrophage apoptosis and M1-to-M2 repolarization.
- This targeted nanoparticle system exhibits potent anti-inflammatory activity and therapeutic potential for RA.
- FA-AgNPs demonstrate excellent biosafety and clearance profiles, highlighting their promise for clinical translation.
More Related Videos
09:36Polyethyleneimine-coated Iron Oxide Nanoparticles as a Vehicle for the Delivery of Small Interfering RNA to Macrophages In Vitro and In Vivo
Published on: February 5, 2019
07:15In vivo Macrophage Imaging Using MR Targeted Contrast Agent for Longitudinal Evaluation of Septic Arthritis
Published on: October 20, 2013